China proposes new rules to address perceived anti-competitive practices in the pharmaceutical industry

On 14 August 2017, the National Development and Reform Commission ("NDRC") released a draft of the Guidelines on Pricing Conduct by Business Operators for Drugs in Shortage and Active...

Blog Post

Excessive pricing in pharmaceutical products attracts the European Commission’s attention

In recent years competition authorities in a number of EU Member States have stepped up in their pursuit against companies active in the Life Sciences sector for excessive pricing. Last...

Published Works

Genentech – Is the right to receive royalties for a revoked or non-infringed patent compatible with the EU law on restrictive agreements?

This article was published as a case study in the November 2016 issue of Competition Policy Research, a journal published by the Electronic Intellectual Property Center, Ministry of...

Loading data